Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases.

Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA.
The American journal of surgical pathology (Impact Factor: 4.59). 06/2009; 33(8):1241-8. DOI: 10.1097/PAS.0b013e3181a1ff41
Source: PubMed

ABSTRACT Noninvasive urothelial carcinoma (UC) with glandular differentiation in the absence of infiltrating carcinoma is a rare entity that has not been well characterized. We retrieved 24 cases of noninvasive UC of the bladder with glandular differentiation on biopsy (n=20) or transurethral resection (n=4) without an associated invasive component. The cases were identified from the consult files of one of the authors between 1992 and 2008. Mean patient age at diagnosis was 70 years (range: 48 to 87 y) and 75% were male. Half of the cases were pure noninvasive UC with glandular differentiation; half were associated with either carcinoma in situ or high-grade noninvasive papillary carcinoma. The glandular component consisted of 1 or more patterns: papillary (46% of cases), glandular (42%), cribriform (33%), and flat (25%). Mitoses, apoptosis, and necrosis were identified in 83%, 67%, and 17% of the biopsies, respectively. One case was a recent diagnosis, and 5 patients either refused treatment or were lost to follow-up. Of the 18 patients with available follow-up information, 9 (50%) did not develop invasive carcinoma; the remaining 9 (50%) eventually developed an invasive bladder tumor. Of these, 2 were small cell carcinoma, 3 were poorly-differentiated UC (2 of these developed widespread metastases), and 4 were UC, not otherwise specified. In both instances of eventual small cell carcinoma, and in 2 of the 3 cases of poorly-differentiated UC, the initial biopsy consisted of pure noninvasive UC with glandular differentiation without carcinoma in situ or noninvasive papillary carcinoma. Of note, none of the patients in the study developed invasive adenocarcinoma.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Upper urinary tract urothelial cell carcinomas (UUT-UCs) are uncommon and are defined as urothelial carcinoma involving the urinary tract from the renal calyces, renal pelvis to the distal ureter. One well-known an peculiar histopathological finding in UUT-UC is urothelial carcinoma with intratubular spread (retrograde spread within renal tubules). However, this special feature has not been systematically studied. We therefore collected a total of 53 consecutive cases of upper urinary tract urothelial carcinomas (UUT-UCs), and studied the clinical and pathological features of intratubular spread (IS). A cocktail stain comprised of antibodies PAX8 and p63 together with PAS was validated and employed to facilitate the study of intratubular spread. Seventeen cases (31.5%) showed intratubular spread demonstrated by either H&E stain and/or the cocktail stain. All of the 17 cases wit intratubular spread had tumor involvement of the renal calyx; the majority of these (14/17, 82.4%) were high grade urothelial carcinoma and the remainder (3/17, 17.6%) were low grade. 4 of 17cases (23.5%) were non-invasive. We classified intratubular spread into 4 different types, based on histopathological patterns: pagetoid, typical, florid, and secondary invasion from intratubular spread. In conclusion, study shows intratubular spread of urothelial carcinoma is fairly common phenomenon in UUT-UC and is associated with a variety of clinical-pathological features. High grade UUT-UC tends to have more extensive intratubular spread and secondary invasion into renal parenchyma. Distinct morphological characteristics as well as the staining pattern from a unique cocktail stain help to identify and evaluate intratubular spread of urothelial carcinoma. Recognizing these different types of intratubular spreading (IS) is crucial for accurate staging of some upper urinary tract urothelial carcinomas (UUT-UCs).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review The scoring system used after transurethral resection of the bladder (TURB) to guide clinical decision-making regarding nonmuscle invasive bladder cancer (NMIBC) largely assumes that NMIBCs are pure urothelial carcinomas and does not take into account the role of variant histology. This review outlines pathological and clinical characteristics of major histological variants to determine their potential impact in therapeutic strategies for the management of NMIBC. Recent findings Assessing the presence of histological variants in NMIBCs after TURB currently remains challenging because of limited tissue sample sizes. However, the presence of these variants often indicates poor prognosis with increased risk for recurrence and progression. Among them, only the following histological variants are indications for Bacillus Calmette-Guerin intravesical instillations: squamous or glandular differentiations and deceptively benign or lymphoepithelioma-like carcinomas. However, patients diagnosed with any other variants should be promptly considered for early radical cystectomy, and only those with small cell carcinoma might benefit from neoadjuvant chemotherapy with a neuroendocrine-specific regimen. Summary Based on the available literature (e.g., small case studies and retrospective studies), the existence of histological variants after TURB appears to massively impact NMIBC outcomes.
    Current Opinion in Urology 07/2014; 24(5). DOI:10.1097/MOU.0000000000000086 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The true clinical significance of variant histology is controversial and diagnosis is challenging, especially in the setting of nonmuscle invasive (NMI) disease. If the presence of variant architecture in NMI identifies a high-risk population with a worse prognosis and better suited for early aggressive intervention (i.e., radical cystectomy), then treatment recommendations should reflect this notion. This review outlines the current evidence and determines whether histologic variants should change management of patients with nonmuscle invasive bladder cancer.
    Current Opinion in Urology 06/2014; 24(5). DOI:10.1097/MOU.0000000000000089 · 2.12 Impact Factor